Bristol-Myers Squibb Co (BMYMP.PK) News| Reuters.com
Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

1,231.90USD
6 Jun 2016
Change (% chg)

-- (--)
Prev Close
$1,231.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
17
52-wk High
$1,231.90
52-wk Low
$991.88

Select another date:

Wed, Jun 15 2016

BRIEF-PeptiDream achieves milestone for initiation of clinical development for bristol-myers squibb's first collaboration product candidate

* Says it has earned a milestone for the dosing of a first patient in a clinical trial by its alliance partner, Bristol-Myers Squibb Company (BMS)

BRIEF-Bristol-Myers announces phase 2 data for Opdivo studies

* Says Opdivo demonstrated objective response rate of 66.3% in classical Hodgkin lymphoma patients

BRIEF-Bristol-Myers Squibb announces new rheumatoid arthritis research

* Announces new rheumatoid arthritis research and real-world data at the annual European Congress Of Rheumatology (EULAR 2016) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

BRIEF-Bristol-Myers Squibb declares qtrly dividend of $0.38/shr

* Declared a quarterly dividend of $0.38 per share on $0.10 par value common stock of corporation Source text for Eikon: Further company coverage:

BRIEF-Bristol-Myers Squibb, MD Anderson announce new collaboration focused on lung cancer

* Bristol-Myers Squibb and MD Anderson announce new research collaboration in immuno-oncology focused on lung cancer

BRIEF-Bristol-Myers Squibb posts data from trials evaluating Opdivo, Yervoy regimen

* Bristol-Myers Squibb -long-term data from two trials evaluating opdivo and yervoy regimen in advanced melanoma continues to validate co's immuno-oncology combination approach Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Case to Watch: California to weigh jurisdiction for out-of-state plaintiffs

The California Supreme Court is set to decide whether non- residents can sue pharmaceutical giant Bristol-Myers Squibb in its state courts, in an appeal that could clarify what presence companies must have in California in order to be sued there by out-of-state plaintiffs.

BRIEF-Bristol-Myers Squibb says Health Canada approved Daklinza in combination with Sofosbuvir

* Myers squibb announces health canada's approval of daklinza in combination with sofosbuvir

BRIEF-Inovalon Holdings announces agreement with Bristol-Myers Squibb

* Inovalon announces agreement with Bristol-Myers Squibb to focus on real world outcomes & value-based contracting initiatives Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Bristol-Myers Squibb presents two-year overall survival data on Opdivo

* Two-Year overall survival data from two pivotal opdivo (nivolumab) trials demonstrate sustained benefit in patients with advanced non-small cell lung cancer

Select another date: